{
  "trial_id": "NCT02237261",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Newly diagnosed multiple myeloma requiring systemic treatment (according to CRAB criteria as specified in the appendix I) with following characteristics: Subject is not a candidate for high-dose chemotherapy and stem cell transplantation due to age, presence of comorbidities likely to have a negative impact on tolerability of HDT-SCT, or subject preference",
      "label": "met"
    },
    {
      "criterion": "Measurable disease, defined as any quantifiable monoclonal protein value, defined by at least one of the following three measurements (Durie et al., 2006): Serum M-protein \u2265 10g/l or Urine light-chain (M-protein) of \u2265 200 mg/24 hours or Serum FLC assay: involved FLC level \u2265 10 mg/dl provided sFLC ratio is abnormal",
      "label": "met"
    },
    {
      "criterion": "Age>18 years",
      "label": "met"
    },
    {
      "criterion": "WHO performance status 0-3 (WHO=3 is allowed only when related to MM and not to co-morbid conditions) (see appendix III)",
      "label": "unknown"
    },
    {
      "criterion": "All patients must be willing and capable to use adequate contraception during the complete therapy",
      "label": "met"
    },
    {
      "criterion": "All patients must agree to abstain from donating blood while on study",
      "label": "met"
    },
    {
      "criterion": "Ability to understand character and individual consequences of the clinical trial",
      "label": "unknown"
    },
    {
      "criterion": "Written informed consent (must be available before enrolment in the trial)",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patient has known hypersensitivity to bortezomib, bendamustine and prednisone or to any of the constituent compounds (incl. boron and mannitol).",
      "label": "triggers"
    },
    {
      "criterion": "Systemic AL amyloidosis (except for patients with AL amyloidosis of the skin or the bone marrow)",
      "label": "triggers"
    },
    {
      "criterion": "Chemotherapy or radiotherapy during the past 5 years except patients with local radiotherapy in case of local myeloma progression. (Note: patients may have received a cumulative dose of up to 160 mg of dexamethasone or equivalent as emergency therapy within 3 weeks prior to study entry.)",
      "label": "triggers"
    },
    {
      "criterion": "Plasma cell leukemia which requires the presence of 20% of plasma cell in peripheral blood leukocytes and at least 2 plasma cells/nl.",
      "label": "triggers"
    },
    {
      "criterion": "Severe cardiac dysfunction (NYHA classification III-IV, see appendix III)",
      "label": "triggers"
    },
    {
      "criterion": "Significant hepatic dysfunction (serum bilirubin \u2265 2 mg/dl or ASAT and/or ALAT \u2265 2.5 times normal level), unless related to myeloma",
      "label": "triggers"
    }
  ],
  "notes": "Patient has multiple comorbidities, including systemic amyloidosis, which may impact tolerability of HDT-SCT.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT02237261",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}